Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,775 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,499 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,528)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03377023 | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | H. Lee Moffitt Cancer Center and Research InstituteOTHER |
| 1 |
| Apr 2, 2026 |
| clinicaltrials |
| NCT04245514 | Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 90 | Swiss Cancer InstituteOTHER | 2 | Apr 2, 2026 | clinicaltrials |
| NCT04925583 | Magnetic Resonance Guided Adaptive Stereotactic Body Radiotherapy for Lung Tumors in Ultracentral Location(MAGELLAN) | active not recruiting | Phase 1 | 38 | University Hospital HeidelbergOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03126630 | Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | active not recruiting | Phase 1 / Phase 2 | 49 | National Cancer Institute (NCI)NIH | 2 | Apr 1, 2026 | clinicaltrials |
| NCT03923270 | Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer | active not recruiting | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04948060 | Tribally Engaged Approaches to Lung Screening (TEALS)(TEALS) | active not recruiting | N/A | 275 | University of OklahomaOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05318027 | ChatBot and Activity Monitoring in Patients Undergoing Chemoradiotherapy | active not recruiting | Phase 2 | 70 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06430866 | Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)(Eucalyptus) | active not recruiting | Phase 3 | 163 | AmgenINDUSTRY | 18 | Apr 1, 2026 | clinicaltrials |
| NCT04607954 | Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer | active not recruiting | Phase 2 | 29 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03433469 | Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery | active not recruiting | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT04129502 | TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | active not recruiting | Phase 3 | 354 | TakedaINDUSTRY | 24 | Mar 30, 2026 | clinicaltrials |
| NCT04881916 | Immune and Genomic Markers in ALK+ NSCLC | active not recruiting | — | 100 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05087251 | The Transitions Project: Efficacy Trial | active not recruiting | N/A | 100 | Massachusetts General HospitalOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT05160922 | Crizotinib Continuation Clinical Study | active not recruiting | Phase 4 | 27 | PfizerINDUSTRY | 5 | Mar 30, 2026 | clinicaltrials |
| NCT03654105 | Screening and Multiple Intervention on Lung Epidemics(SMILE) | active not recruiting | Phase 2 | 2,000 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04450043 | The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance | active not recruiting | N/A | 21 | Massachusetts General HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05766046 | Lung Cancer Prevention Screening Programme in Italy(RISP) | active not recruiting | N/A | 7,324 | Ugo PastorinoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06320184 | AI for Lung Cancer Risk Definition in Computed Tomography Screening Programs | active not recruiting | — | 650 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07491211 | Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases | active not recruiting | — | 300 | Fudan UniversityOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06767046 | KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors | active not recruiting | Phase 1 | 8 | Corregene Biotechnology Co., LtdINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05680922 | DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 1 | 41 | Legend Biotech USA IncINDUSTRY | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04268550 | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) | active not recruiting | Phase 2 | 124 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05970913 | PET-CT Predicting Lymph Nodes Metastasis | active not recruiting | — | 280 | Fudan UniversityOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03068663 | Microbiota and the Lung Cancer(MICA) | active not recruiting | N/A | 40 | Centre Jean PerrinOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT05306288 | CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung(DELFI-L201) | active not recruiting | — | 11,935 | Delfi Diagnostics Inc.INDUSTRY | 2 | Mar 19, 2026 | clinicaltrials |
| NCT06671379 | A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | active not recruiting | Phase 3 | 498 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04379635 | Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 3 | 453 | BeiGeneINDUSTRY | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
| NCT05832112 | Outside the Cage (OTC) Robotic Lobectomy(OTC-RATS) | active not recruiting | N/A | 100 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06726265 | Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | active not recruiting | Phase 3 | 756 | Immutep S.A.S.INDUSTRY | 27 | Mar 18, 2026 | clinicaltrials |
| NCT04802174 | Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers | active not recruiting | Phase 1 / Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05456867 | A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia(NIS durvalumab) | active not recruiting | — | 250 | AstraZenecaINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07396467 | Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis(IPF-LC-IO) | active not recruiting | — | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05364073 | Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations | active not recruiting | Phase 1 | 160 | ArriVent BioPharma, Inc.INDUSTRY | 11 | Mar 13, 2026 | clinicaltrials |
| NCT04897022 | A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma | active not recruiting | Phase 1 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05401786 | Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC(RAD-IO) | active not recruiting | Phase 2 | 54 | The Netherlands Cancer InstituteOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT05853887 | Liquid Biopsy Based NGS in Newly Diagnosed NSCLC(iNUDGE) | active not recruiting | N/A | 260 | Charu AggarwalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06277388 | Evaluation of Impedance Cardiography for Assessing Hemodynamic Shifts in Patients With LA-NSCLC During Treatment. | active not recruiting | — | 231 | Sun Yat-sen UniversityOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06301295 | Feasibility of Targeted Bronchial Washing for Molecular Testing by Next Generation Sequencing in Early-stage Lung Cancer | active not recruiting | N/A | 50 | Pusan National University HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03875820 | Phase I Trial of Defactinib and VS-6766.(FRAME) | active not recruiting | Phase 1 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05044468 | EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement | active not recruiting | Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05237453 | Pulmonary Magnetic Resonance-guided Online Adaptive Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer(PUMA) | active not recruiting | N/A | 30 | University Hospital HeidelbergOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05499390 | AK112 in Advanced Non-Small Cell Lung Cancer | active not recruiting | Phase 3 | 398 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT05904379 | AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 233 | AkesoINDUSTRY | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02701699 | 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer(FAZA Lung) | active not recruiting | N/A | 36 | University Health Network, TorontoOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT05254795 | Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care(PRiMAL) | active not recruiting | N/A | 659 | Timothy MullettOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT03260491 | U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | active not recruiting | Phase 1 | 312 | Daiichi SankyoINDUSTRY | 6 | Mar 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 6, 2026source: clinicaltrials